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Improvement in Lung Cancer Outcomes With
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In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung
cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit
and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients,
selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibi-
tors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted
agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role
in the treatment, detection, and management of common toxicities and in providing emotional support.
Therefore this review integrates molecular profile assessment with evidence of the efficacy and toxicity
of tyrosine kinase inhibitors to provide an updated overview of the treatment of non-small-cell lung
cancer, which radically changed after the advent of targeted therapies. It also aims to promote a more
intensive and interactive collaboration between specialists and family physicians in the management of
all phases of cancer care. (J Am Board Fam Med 2015;28:124–133.)
Keywords: Cancer, Drug Therapy, Lung Cancer, Medical Oncology, Non-Small-Cell Lung Cancer, Tyrosine Kinase
The past decade has witnessed a silent revolution in
the war against cancer, thanks to the advent of new
therapies, which target speciﬁc mutations related to
cancer cell proliferation and survival in different
types of tumors. Among all cancers, lung cancer
remains the leading cause of cancer-related death
in most countries, with 159,260 expected deaths in
the United States in 2014. Lung cancer occurs
predominately in people between 50 and 70 years
old, but the risk of developing this cancer reaches a
peak in people older than 70 years. Lung cancer
incidence decreased in the past two decades in
several countries, including the United States, fol-
lowing a decreased rate of smoking. At the same
time, the incidence among women, including for-
mer or never smokers, is rapidly increasing.1 The
discovery of “oncogenic driver mutations” and the
subsequent development of tailored agents has rad-
ically changed the treatment of lung cancer in ten
years, leading to the development of personalized
strategies.2,3 Non-small-cell lung cancer (NSCLC)
was traditionally classiﬁed, based on histologic fea-
tures, as adenocarcinoma, squamous cell carci-
noma, and other nonspeciﬁed subtypes, which rep-
resent about 55%, 35%, and 10% of all NSCLC
cases, respectively. In the early 1990s treatment
approaches available for patients with lung cancer
were poor, with a median survival of 2 to 4
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months.4 The introduction of platinum-based
combinations with third-generation agents such as
gemcitabine, vinorelbine, and docetaxel signiﬁ-
cantly improved survival outcomes, which led to a
“plateau” of about 10 to 11 months’ median sur-
vival; nowadays these combinations are still consid-
ered the standard of care for the majority of pa-
tients with NSCLC.5 Subsequently, signiﬁcant
advances have been made with the introduction of
new, more speciﬁc cytotoxic drugs, such as pem-
etrexed, with improved efﬁcacy, especially against
the non–squamous cell carcinoma subtype. The
addition of this agent led to a further improvement
in survival to 12 to 13 months6 and up to14 months
with the introduction of maintenance treatment.7
Furthermore, the discovery of key oncogene alter-
ations contributed to the gradual shift of NSCLC
classiﬁcation from a histologic- to molecular-based
proﬁle. In fact, even when the histologic subtype is
a factor when selecting among different chemo-
therapies, the tumor molecular features are now
crucial for the selection of patients to receive new
tailored agents. The ﬁrst example is the discovery
of speciﬁc epidermal growth factor receptor
(EGFR) mutations and ALK gene rearrangements
in a subset of patients with NSCLC, leading to the
development of the EGFR tyrosine kinase inhibi-
tors (TKIs) erlotinib, geﬁtinib, and afatinib and the
ALK inhibitors crizotinib and ceritinib, which cur-
rently are the only targeted drugs approved for the
treatment of NSCLC.8 New driver mutations were
recently identiﬁed in both adenocarcinoma and
squamous cell carcinoma, and several ongoing trials
are investigating the activity of new potential target
agents. The introduction of new tailored ap-
proaches in clinical practice changed the lung can-
cer treatment strategy; new emerging toxicities re-
quire active involvement and collaboration of
family physicians in all phases of care. Family phy-
sicians, with their ongoing relationships with pa-
tients and the patient’s family and caregivers, has an
important role in the treatment, detection, and
management of common toxicities and in providing
emotional support. Family physicians are also well
positioned to identify and address unmet nonmed-
ical and medical needs that have such a crucial
inﬂuence on quality of life, playing a key role in
mediating the relationship between the medical on-
cologist and the patient. Therefore we believe that
family physicians should be up to date with these
radical changes in clinical oncology, especially
with regard to the treatment of common malig-
nancies such as NSCLC (Figures 1 and 2).
EGFR Pathway and EGFR Inhibitors
EGFR Mutations
EGFR-activating mutations are the most frequent
driver mutations in NSCLC, reported in about
40% to 60% of Asian,9–11 15% to 20% of
white,12,13 and about 30% of Latin-American14 pa-
tients with NSCLC; they are very important as
clinical predictors of EGFR TKI sensitivity and
efﬁcacy.15 The most frequent mutations are exon19
deletions (20 variant types) and a mutation at
codon 858 in exon21 (L858R), accounting for 90%
of overall EGFR mutations.16 Several in vitro stud-
ies demonstrated that these mutations increased
EGFR activity and were responsible for cancer cell
proliferation and survival, also leading to angiogen-
esis, tumor invasion, and metastatic potential. Fol-
lowing molecular interaction with the receptor,
small-molecule TKIs speciﬁcally inhibit EGFR and
are capable of inactivating the downstream aber-
rant signaling pathways.
EGFR TKIs
EGFR TKIs represent the mainstream in targeted
therapy in NSCLC, leading to improvements in
the median survival rates and quality of life for
patients with tumors harboring EGFR-activating
mutations. Geﬁtinib is available as ﬁlm-coated tab-
lets that contain 250 mg of the active compound,
taken once a day. Erlotinib is available in 3 dose-
strength tablets: 25, 100, and 150 mg; the recom-
mended dose is 150 mg once a day. Both of these
drugs are recommended as ﬁrst-line treatment for
patients whose tumors harbor EGFR-activating
mutations, but erlotinib was also approved as a
second-/third-line treatment for patients with un-
known EGFR mutational status.17 Several random-
ized studies included in a recent meta-analysis,
however, showed that erlotinib and geﬁtinib have
lower efﬁcacy than standard chemotherapy in pre-
treated patients with EGFR wild-type tumors18,
suggesting that the EGFR mutation is a predictive
biomarker for EGFR TKI efﬁcacy in a second-line
setting. Both drugs should be taken 1 hour before
or 2 hours after lunch, whereas only erlotinib-
treated patients should avoid drinking grapefruit
juice, reduce or stop smoking, and avoid taking
proton pomp inhibitors 4 hours before or 2 hours
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after the TKI’s uptake to avoid drug’s interactions.
Afatinib, another TKI, has been recently approved
by the US Food and Drug Administration (FDA)
and European Medical Agency as a ﬁrst-line treat-
ment of NSCLC in patients whose tumors harbor
EGFR-activating mutations, at a dose of 40 mg
once daily.
At least 8 different clinical trials comparing
front-line EGFR TKI treatment with standard
platinum chemotherapy in patients with EGFR-
Figure 1. Molecular subsets of lung cancer.
Figure 2. Treatment algorithm in first-line metastatic non-small-cell lung cancer (NSCLC). EGFR, epidermal growth
factor receptor; PS, performance status; TKI, tyrosine kinase inhibitor; WT, wild-type.
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mutated NSCLC have shown that targeted treat-
ment is better than standard chemotherapy in this
selected patient population, leading to a signiﬁcant
improvement in survival, which reached a plateau
of 24 to 30 months11,15,19–24 (Table 1). Such ﬁnd-
ings suggest that testing tumors for speciﬁc activat-
ing mutations, and tailoring the therapeutic ap-
proach, may optimize patients’ survival outcomes.
Several studies showed a higher occurrence of
EGFR-activating mutations in a subgroup of pa-
tients with NSCLC reporting some clinical fea-
tures, such as “women, nonsmokers, Asian race and
especially adenocarcinoma subtype,” which could
be considered as clinical predictive factors for TKI
sensitivity. Otherwise, a signiﬁcant percentage of
patients without the aforementioned clinical fea-
tures also was positive for EGFR-activating muta-
tions.25 Based on these ﬁndings, the American So-
ciety of Clinical Oncology recommends EGFR
mutation testing before treatment with EGFR
TKIs in the management of all patients with ad-
vanced lung cancer.26 While most patients with
EGFR-mutated NSCLC present good initial re-
sponses to treatment with geﬁnitib or erlotinib,
they invariably develop resistance to EGFR
TKIs,25 translating into clinical disease progression
usually after 10 to 12 months of treatment. In
clinical practice this often interrupts the current
targeted treatment and requires a switch to a stan-
dard platinum-doublet chemotherapy. In the past
year, however, an improved understanding of the
mechanisms of underlying resistance to EGFR
TKIs emphasizes the importance of a genotype-
guided approach to therapy. Several cell-based
studies identiﬁed a second EGFR gene mutation,
T790M, as the leading cause of acquired resistance
to ﬁrst-generation EGFR TKIs in about 50% of
patients.27 This observation guided the develop-
ment of a new generation of irreversible EGFR
inhibitors, including CO1686 and AZD9291, capa-
ble of speciﬁcally targeting and inactivating the
T790M mutation.28,29 Another signiﬁcant group of
cancers (approximately 20%) acquire resistance to
EGFR TKIs following the ampliﬁcation of the
mesenchymal–epithelial transition (MET) factor
receptor tyrosine kinase, which activates different
EGFR signaling pathways.30 Other resistance-re-
lated processes include Her-2 ampliﬁcation (12%),
phenotypic change from NSCLC to small-cell lung
carcinoma (4%), and modiﬁcations in other parallel
signaling pathways.31 Several ongoing studies will
contribute to an improved understanding of the
molecular basis of acquired resistance, and new
therapeutic approaches will improve the efﬁcacy of
anticancer regimens in NSCLC.
ALK Translocation and ALK Inhibitors
EML-ALK Chromosome Rearrangement
In 2007 Soda and colleagues32 discovered another
driver mutation in NSCLC: the EML4-ALK fusion
gene, which is the consequence of a chromosomal
rearrangement, resulting in a fusion between the
N-terminal portion of the EML4 protein and the
intracellular region of the receptor ALK. EML4–
ALK fusion leads to a ligand-independent, consti-
tutive activation of the rearranged ALK receptor,
which is responsible for both tumor cell prolifera-
tion and survival. ALK translocation occurs in
about 3% to 7% of patients with NSCLC33 and is
Table 1. Randomized Studies Comparing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and
Chemotherapy in First-Line Treatment of Non-Small-Cell Lung Cancer
Study TKI EGFR mutations (n) ORR (TKI vs CT) (%)
Median PFS
(TKI vs CT) (months)
OS (TKI vs CT)
(months/HR)
First-Signal Geﬁtinib 27 84 vs 37 8.4 vs 6.7 30.6 vs 26.5
IPASS Geﬁtinib 132 71 vs 47 9.8 vs 6.4 21.6 vs 21.9
NEJGSG002 Geﬁtinib 228 74 vs 29 10.8 vs 5.4 27.7 vs 26.6
WJTOG3405 Geﬁtinib 172 62 vs 32 9.2 vs 6.3 NA
OPTIMAL Erlotinib 154 83 vs 36 13.7 vs 4.6 NA
EURTACC Erlotinib 173 58 vs 15 9.7 vs 5.2 NA
Lux-Lung 3 Afatinib 308 56 vs 23 13.6 vs 6.9 HR: 1.12
Lux-Lung 6 Afatinib 364 67 vs 23 11 vs 5.6 HR: 0.95
CT, chemotherapy; EGFR, epidermal growth factor receptor; HR, hazard ratio; NA, not available; ORR, objective response rate; OS,
overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.
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not mutually exclusive with EGFR and KRAS gene
mutations. Data obtained from different studies
show that it is more frequent in Eastern Asian
patients, those with adenocarcinomas histotypes,
light or never smokers, women, and younger pa-
tients. However, it was also reported in patients
with squamous or adenosquamous carcinomas and
in smokers, albeit at a much lower rate.33,34 Fur-
thermore, the ALK-positive tumor phenotype
seems to be associated with worse survival and an
increased risk of brain and liver metastases,35
whereas it is resistant EGFR TKI therapy33,34 and
has higher sensitivity to the cytotoxic agent pem-
etrexed.36 Immune ﬂuorescence in situ hybridiza-
tion is currently considered the standard test, ap-
proved for the detection of ALK -rearrangements
in tumor samples (Figure 3).
EML-ALK Inhibitors
Crizotinib is the ﬁrst and actually the only available
ALK inhibitor approved for treatment of ALK-
positive patients with NSCLC, at doses of 250 mg
twice daily (500 mg/day). It is a potent oral ATP
competitor at the ATP-binding pocket of the ALK
receptor, with additional anti-MET and anti-ROS1
activity. The approval and subsequent introduction
of crizotinib in clinical practice was based on the
results of phase I and II trials which showed a
surprising response rate as well as a progression-
free survival rate in ALK-positive pretreated pa-
tients,37–39 leading to an acceleration of the drug
registration procedures, deﬁnitively approved by
the FDA in October 2011. This is the ﬁrst report in
the history of oncology that a drug is approved
based only on the phase I and II data. These results
were subsequently conﬁrmed by a phase III trial
(PROFILE 1007), which showed a signiﬁcant im-
provement of response and survival rates and also
in terms of quality of life for pretreated patients
with NSCLC.40 Today, the drug is still recom-
mended for the treatment of ALK-positive patients
with NSCLC only when progressing after ﬁrst-line
chemotherapy,8 but another randomized phase III
trial, PROFILE 1014, investigated the efﬁcacy of
crizotinib in a ﬁrst-line setting, showing a signiﬁ-
cant survival beneﬁt in this selected subgroup of
patients.41 Unfortunately, because of the develop-
ment of resistance, ALK-positive patients treated
with crizotinib also relapse after a variable period
of sensitivity; this may be related to a second
mutation either in the ATP-binding pocket or
the ampliﬁcation of the ALK fusion gene. Other
less frequent alterations include increased EGFR
phosphorylation and mutation, Kit ampliﬁcation
Figure 3. ALK-positive fluorescence in situ hybridization image of a patient with non-small-cell lung cancer.
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and mutation, and KRAS mutation. Next-gener-
ation ALK inhibitors, developed to overcome
crizotinib resistance, are under investigation in
several early phase studies. One of these com-
pounds, ceritinib, has shown great activity in a
recent phase I study by Shaw et al,42 receiving
approval by the FDA for the treatment of ALK-
rearranged patients with NSCLC who had pro-
gressed or were intolerant to crizotinib. Since
these second-generation target drugs have vari-
able efﬁcacy against some speciﬁc mutations, mo-
lecular testing after progression is required to
ensure the best tailored approach43 (Table 2).
Emerging Toxicities and Management
EGFR Inhibitors’ Toxicity
TKIs present a good tolerability proﬁle, with a
signiﬁcantly lower incidence of side effects, such as
myelosuppression, nausea, vomiting, fatigue, and
neurotoxicity, when compared with chemotherapy.
On the other hand, new adverse events, such as skin
rash, diarrhea, and asymptomatic hypertransami-
nasemia, emerged as a speciﬁc result of silencing
the EGFR pathway in healthy cells, whereas severe
toxicities were less frequently reported.15,22,23 Skin
toxicity is the most common adverse effect associ-
ated with TKIs, reported in 80% of patients
treated with these drugs. Although 20% of pa-
tients have severe symptoms,44 skin toxicity is vis-
ible and often causes physical and emotional dis-
comfort, resulting in a signiﬁcant impact on quality
of life.45 Such toxicity is related to dose reductions
in 60% of patients or discontinuation of treatment
in 32%,46 with subsequent poor clinical outcomes
and an increase in management costs. Thus it is
essential for family physicians to be aware of these
dermatologic side effects to ensure appropriate and
early management. Skin rash is characterized by a
monomorphic papulopustular eruption, often con-
ﬁned to seborrheic areas (midfacial region and the
upper trunk), which consists of erythematous fol-
licular papules that evolve into pustules and some-
times may become infected, usually with Staphylo-
coccus aureus, forming yellow crusts.47 The reactive
treatment of skin rash depends on its severity. Dif-
ferentiating low-grade toxicity (grade 2), character-
ized by eruption with papules or pustules covering
30% of the body surface without symptoms in-
terfering with daily activities, from moderate to
high-grade toxicity (grade 3), characterized by
eruption with papules or pustules covering 30%
of the body surface, with symptoms that interfere
with daily activities, is important. In grade 2 toxic-
ity, local treatment with an antibiotic (clindamycin
1% gel, erythromycin 3% gel, or metronidazole
1% gel) is recommended. In grade 3, in addition to
the local treatment, systemic treatment with oral
tetracyclines for 4 weeks and oral corticosteroids
for 10 days is recommended. If no improvement
occurs, discontinuation or interruption of treat-
ment may be indicated. For nonresponsive and
grade 4 toxicity, which is characterized by general-
ized rash or severe symptoms, systemic treatment
with intravenous corticosteroids, antibiotics, and
hydration—or even hospitalization for emergency
treatment—may be considered.48,49 Although the
toxicity proﬁle between different TKIs is compa-
rable, it seems to be somewhat worse for afatinib
than for erlotinib or geﬁtinib. Furthermore, data
reported from several trials and a recent meta-
Table 2. Clinical Trials with Crizotinib in ALK-positive Patients
Study Phase
Patients with NSCLC,
AKT (n) ORR (%) PFS (months) Author
PROFILE 1001 Phase I 149 60.8 (95% CI, 52.3–68.9) 9.7 (95% CI, 7.7–12.8) Camidge 2012
PROFILE 1005 Phase II 261 60 (95% CI, 53.6–65.9) 8.1 (95% CI, 6.8–9.7) Kim 2012
PROFILE 1007 Phase III (CZT vs
pemetrexed/
docetaxel)
346 65 vs. 19.5* 7.7 vs 3.0* Shaw 2013
PROFILE 1014 Phase III (CZT vs
cisplatin or
carboplatin 
pemetrexed)
343 74 vs. 45* 10.9 vs 7.0* Mok 2014
*P  .0001.
CZT, crizotinib; CI, conﬁdence interval; NA, not available; NSCLC, Non-small-cell lung cancer; ORR, objective response rate; PFS,
progression-free survival.
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analysis50 suggested that patients reporting skin
rash had better survival than those without skin
toxicity. Thus rash can be considered an indepen-
dent, clinical, early predictor of TKI efﬁcacy, and
providing this information to patients could help
them better tolerate toxicity-related physical and
emotional discomfort (Figure 4 and Table 3).
ALK Inhibitor Toxicity
Patients treated with crizotinib reported fewer tox-
icities and improved results in lung cancer symp-
tom control and in global quality of life when
compared with patients treated with chemotherapy.
The most frequent treatment-related adverse ef-
fects were visual disorders, such as visual impair-
ment, photopsia, blurred vision, vitreous ﬂoaters,
photophobia, and diplopia. Gastrointestinal events
such as nausea, vomiting, diarrhea, and constipa-
tion are generally mild, can be managed with a
supportive care, and tend to decrease in severity
after the ﬁrst few weeks of therapy. Because ele-
vated liver enzymes are frequently observed (40%
to 70%) with grade 3 in 7% to 15% of patients,
monitoring them every 2 weeks of the crizotinib
therapy’s duration is strongly recommended. Pe-
ripheral edema, which is a common side effect, may
be managed with standard medical intervention.
Finally, about 69% of patients experienced at least
1 episode of sinus bradycardia (heart rate 60
bpm).40 With regard to ceritinib, the most grade 3
to 4 common terminology criteria for adverse
events were diarrhea, fatigue, hyperglycemia, hy-
pophosphatemia, increased transaminases and
lipase concentrations, and anemia.42
Future Perspectives and Conclusions
The introduction of the EGFR TKIs geﬁtinib,
erlotinib, and afatinib and the ALK inhibitors
crizotinib and ceritinib represent the most impor-
tant innovations in NSCLC treatment over the
past ten years. By targeting the main pathways of
NSCLC pathophysiology, these new drugs signif-
icantly improved survival rates and quality of life in
a highly selected subgroup of patients, sparing
them from toxic chemotherapy approaches; for the
vast majority of patients, however, chemotherapy
remains the only potential treatment. Although the
target agents were approved only for EGFR and
ALK gene alterations,8 the number of potential
biomarkers is rapidly increasing. New driver muta-
tions were identiﬁed in both adenocarcinoma, such
as K-Ras, Her-2-neu, MET, N-Ras, BRAF, MAP-
2-K, PIK3CA, AKT1, ROS, and RET mutations, and
squamous cell carcinoma, such as FGFR-1 ampliﬁ-
cation, EGFR mutation and ampliﬁcation, PIK3CA
mutation and ampliﬁcation, PTEN loss, and DDR2,
but 50% of mutations remain unknown.51,52 Sev-
eral ongoing trials are investigating the activity of
new target agents in patients with these mutations
(Table 4). The rapidly growing number of targeted
treatment options will lead to new insight into
Figure 4. Cutaneous toxicities, or “skin rash”, caused by tyrosine kinase inhibitors in patients with non-small-cell
lung cancer.
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personalized treatment in the near future. Nowa-
days, new techniques such as “next-generation-se-
quencing” make possible the creation of a molecu-
lar–genomic proﬁle of every patient’s tumor, based
on the analysis of either a single tissue sample,
circulating tumor cells, or circulating tumor DNA.
Therefore the need for close collaboration between
health professionals, including medical oncologists,
molecular biologists, pathologists, and family phy-
sicians, will increase. The role of family physicians
remains critical because of their unique and privi-
leged position of seeing patients on a daily basis;
thus they should be updated by other experts on
scientiﬁc discoveries relevant to their everyday
practice and more frequently involved in the global
view of care in all the phases.
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Anti-FGFR1 Ponatinib
Dovitinib
Cediranib
Anti-DDR2 Dasatinib
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